Sales of eye care pharmaceuticals rose to $379.2 million at Allergan for the second quarter ended June 30, or $54.2 million more than in the same period a year ago. Total revenues were up to $801.7 million from $594.6 million, with product revenues up by 33.2 percent, thanks in part ...
Already an Eyewear Intelligence subscriber? Sign in here.
Buying a membership today will give you:
Or sign-up for a trial month for just 9,90€. To continue reading this article register now.